COVID-19 pandemic and lockdown stress consequences in people with and without Irritable Bowel Syndrome

por Sabate, J.-M., Deutsch, D., Melchior, C., Entremont, A., Mion, F., Bouchoucha, M., Façon, S., Raynaud, J.-J., Zerbib, F., Jouët, P.
Publicado 2021

Randomised clinical trial: the 5‐HT4 agonist revexepride in patients with gastro‐oesophageal reflux disease who have persistent symptoms despite PPI therapy

por Shaheen, N. J., Adler, J., Dedrie, S., Johnson, D., Malfertheiner, P., Miner, P., Meulemans, A., Poole, L., Tack, J., Thielemans, L., Troy, S., Vakil, N., Zerbib, F., Ruth, M.
Publicado 2015

Randomized clinical trial: effect of the 5-HT(4) receptor agonist revexepride on reflux parameters in patients with persistent reflux symptoms despite PPI treatment

por Tack, J, Zerbib, F, Blondeau, K, des Varannes, S B, Piessevaux, H, Borovicka, J, Mion, F, Fox, M, Bredenoord, A J, Louis, H, Dedrie, S, Hoppenbrouwers, M, Meulemans, A, Rykx, A, Thielemans, L, Ruth, M
Publicado 2015